Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia

Bekele Sharew,Ayenew Berhan,Andargachew Almaw,Mulat Erkihun,Tegenaw Tiruneh,Teklehaimanot Kiros,Yenealem Solomon,Mitikie Wondmagegn,Etenesh Wondimu,Abay Teshager,Simegnew Bihonegn,Mihret Tilahun,Birhanu Getie
DOI: https://doi.org/10.1002/jcla.25111
IF: 3.124
2024-10-12
Journal of Clinical Laboratory Analysis
Abstract:According to the examined records, a total of 12,891 presumed pulmonary tuberculosis cases sought TB diagnosis services utilizing the GeneXpert system assay, which was included in this retrospective analysis. Of the total presumptive pulmonary TB patients in the research period, 8.9% (1160/12,891) tested positive for M. tuberculosis, while 7.1% (82/1160) were rifampicin‐resistant. Background Tuberculosis (TB) is a preventable and treatable disease leading to the second death globally. The evolution of drug resistance in Mycobacterium tuberculosis (MTB), particularly rifampicin resistance (RR), has hampered TB control efforts. Thus, this study aimed to provide information regarding the magnitude of MTB and rifampicin resistance among patients tested using the GeneXpert method. Methods A retrospective analysis was carried out at DTCSH. The study included TB registration logbook data from all patients who visited the hospital and were tested for MTB with the Xpert MTB/RIF assay from 2017 to 2024. The laboratory‐based data were entered, cleaned, and analyzed using SPSS version 26 software. Multilogistic regression analysis was employed, and a p value ≤ 0.05 was considered statistically significant. Results A total of 12,981 patient results were included, of which 8.9% (1160/12,981) were MTB‐positive and 7.1% (82/1160) were RR. Individuals aged 15–29 years (AOR = 2.13; 95% CI = 1.55–2.93, p
medical laboratory technology
What problem does this paper attempt to address?